Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Quanscient | $5,667,883 | (Nov 5, 2024)
Weave
United States
- ND
- 31/05/2024
- Unknown
- $10,000,000
Weave Bio is an AI-native, life sciences platform company that provides a technically robust, AI-enabled platform for major pain points inherent in the pharma and biotech industries.
Our flagship product, AutoIND, is the first offering on Weave’s comprehensive Regulatory Automation and Lifecycle Management (ReALM) platform. With AutoIND we streamline the Investigational New Drug (IND) application process and enable drug development teams to build a living record of their therapeutic candidates, delivering significant improvements in both efficiency and quality.
AutoIND automatically generates content based on users’ own source data, regulatory guidelines, and public information. The solution offers a robust, in-platform process for quality review and significantly enhances editing capabilities and oversight for teams. While conventional IND preparation processes can take more than a year, AutoIND can produce a first draft of an IND in a single day and reduce the overall time to generate a final IND submission by over 50%, returning capacity to regulatory teams, lowering costs, and ultimately accelerating the time it takes to get treatments to patients.
For more information, visit weave.bio
- Industry Biotechnology Research
- Website https://www.weave.bio/
- LinkedIn https://www.linkedin.com/company/weavebio/
Related People
Ari CarolineFounder
United States -
New Haven, Connecticut
In my 20+ years working in healthcare and the life sciences, I've never become comfortable. I see systems that don't work, that don't make any sense to me, and can't stop thinking about what simple interventions could make these systems, just better. Technology, particularly machine learning and AI, has a huge role to play in making these systems both faster and better.
At Weave, we focus on one of the most boring, but also one of the most critical, domains in the drug development process, regulatory reporting. Our AutoIND platform will radically accelerate the process of preparing and submitting Investigational New Drug (IND) applications to the FDA.
We turn the complexity of biomedicine into simple, clear narratives, getting new therapies to patients who desperately need them, at the speed of AI.
Miros | $6,535,520 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
Plato | $6,500,000 | (Nov 5, 2024)
cloudsquid | $1,000,000 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Birl | $647,878 | (Nov 5, 2024)
Inquis Medical, Inc. | $40,000,000 | (Nov 5, 2024)
CrossBridge Bio | $10,000,000 | (Nov 5, 2024)